JSR Life Sciences Background

AN1 New Thumbnail



Learn More About the Six Biosimilar Molecules Using Amsphere: Protein A Resin

Currently more than 70 biosimilar mAbs (monoclonal antibodies) are under development and multiple originator mAbs are going off-patent. Protein A resin remains the most important workhorse for the purification of monoclonal antibodies. Protein A resin has a high impact on both development and manufacturing cost, in particular during early stage clinical phases. This application note summarizes the key performance parameters for our high capacity protein A resin, Amsphere A3, for 6 biosimilar molecules of which five are mAbs and one is a Fc-fusion protein.

Download Today.

Enter your information below and receive the application note instantly.